Table 2 Immunosuppression.
From: Benefits of statin therapy within a year after kidney transplantation
Statin (n = 414) | Control (n = 300) | p-value | |
|---|---|---|---|
Induction | 0.650 | ||
Basiliximab, n (%) | 380 (91.8) | 262 (87.3) | |
Anti-thymocyte globulin, n (%) | 38 (9.2) | 32 (10.7) | |
Maintenance | |||
Calcineurin inhibitor, n (%) | 0.022 | ||
Tacrolimus | 389 (94.0) | 287 (95.7) | |
Cyclosporine | 29 (7.0) | 9 (3.0) | |
Prednisolone, n (%) | 394 (95.2) | 233 (77.7) | < 0.001 |
Mycophenolate mofetil, n (%) | 345 (83.3) | 251 (83.7) | 0.423 |
mTOR inhibitor, n (%) | 44 (10.6) | 7 (2.3) | < 0.001 |
Tacrolimus trough level | |||
1-year, ng/mL | 5.8 ± 2.3 | 6.1 ± 2.1 | 0.084 |
2-year, ng/mL | 5.3 ± 2.1 | 5.7 ± 1.9 | 0.011 |
3-year, ng/mL | 5.2 ± 1.8 | 5.8 ± 1.9 | < 0.001 |
4-year, ng/mL | 5.2 ± 1.9 | 5.6 ± 2.1 | 0.024 |
5-year, ng/mL | 5.1 ± 1.8 | 5.7 ± 2.0 | 0.002 |
6-year, ng/mL | 5.1 ± 1.9 | 5.7 ± 2.0 | 0.007 |
7-year, ng/mL | 5.1 ± 1.9 | 5.6 ± 2.2 | 0.036 |
